KLOW Blend – Pre-filled Pen 80mg/3ml

£320.00

Klow Blend is a synergistic peptide formulation intended for advanced research in dermatology and tissue regeneration , composed of BPC-157 10mg , TB-500 (Thymosin Beta-4) 10mg , KPV 10mg and GHK-Cu 50mg .

This combination integrates four peptides with complementary mechanisms that act on different levels of cellular repair and tissue healing.
BPC-157 stimulates fibroblast migration, collagen production, and the formation of new blood vessels by modulating VEGFR2 receptors and the FAK–paxillin pathway.
TB-500 promotes tissue regeneration and angiogenesis by increasing VEGF and activating cell motility, contributing to the repair of muscles, dermis, and connective tissue.
GHK-Cu, a copper-binding tripeptide, promotes collagen synthesis and tissue remodeling, thanks in part to its antioxidant and modulatory action.
KPV (Lys-Pro-Val) is known for its ability to modulate the inflammatory response and for its relevance in skin homeostasis research.

The combined action of these four peptides offers a synergistic effect on the processes of angiogenesis , extracellular matrix remodeling, and cell regeneration dynamics. This synergy makes them of interest for experimental dermatological and tissue research.

Thanks to their complementary interaction, the components of the Klow Blend represent a reference model for the study of the biological mechanisms involved in the processes of cellular regeneration and modulation.

KLOW Blend – Pre-filled Pen 80mg/3ml , Blend BPC-157 + TB-500 + GHK-Cu + KPV is a peptide formulation for preclinical research in tissue regeneration , dermatology , and inflammation modulation . It integrates four peptides with complementary mechanisms: BPC-157 (a stable gastric pentadecapeptide, pro-angiogenic and pro-reparative), TB-500 (a functional derivative of Thymosin Beta-4 , 43 aa, regulator of actin and inflammation), GHK-Cu (a copper-binding tripeptide, pro-collagen, and antioxidant), and KPV (a tripeptide derived from α-MSH, studied for its local immunomodulatory activity). The aim is to exploit multifactorial synergies on angiogenesis, cell migration, ECM remodeling, and redox-cytokine control to accelerate and improve the quality of repair processes.


Biochemical mechanisms of the components

BPC-157. Derived from Body Protective Compound , it has shown effects on the GI tract, liver, pancreas, tendons/ligaments, muscle, cornea, heart, CNS, and nerves in animal models. It acts prominently on nitric oxide (NO) signaling , counteracting the detrimental effect of NO inhibition (e.g., L-NAME) and modulating eNOS by upregulating antioxidant enzymes (e.g., HO-1). Transcriptomic evidence indicates fine-tuning of Egr , Nos (especially eNos ), Srf , Vegr , Plcγ , and Kras , impacting adhesion, thrombosis, and the inflammatory response. Rapid and broad tissue distribution after administration supports a multi-organ action profile.

TB-500 (Thymosin Beta-4). Actin-sequestering peptide that regulates cell motility, growth, and division. In addition to its function on actin, it “ moonlights ” as a transcriptional modulator of NO-synthase, angiogenesis, proliferation, and immune-inflammation pathways: attenuates NF-κB and TLR , reduces cytokines such as TNF-α and IL-6 , and activates PI3K/Akt/eNOS , Notch , Ang1/Tie2 ; modulates TGF-β (anti-fibrosis) and influences Wnt (neo-folliculogenesis). Reported benefits on myocardial regeneration, skeletal muscle, skin/corneal, and CNS. [3] [6] [7]

KLOW Blend – Pre-filled Pen 80mg/3ml, GHK-Cu. A natural complex (Gly-His-Lys + Cu 2+ ) isolated from plasma/saliva/urine, known in dermatology to promote collagen synthesis , fibroblast proliferation , ECM remodeling , and dermal healing . It modulates metalloproteinases and anti-proteases, suppresses pro-inflammatory cytokines (TNF-α, IL-6), enhances antioxidant systems (SOD, glutathione), and coordinates the balance of protein deposition/degradation at the gene level.

KPV. Tripeptide (Lys–Pro–Val) derived from the C-terminal portion of α-melanocyte stimulating hormone (α-MSH), studied in preclinical models for its ability to reduce NF-κB activation and modulate the production of pro-inflammatory cytokines ( TNF-α , IL-6 , IL-1β ). It shows a predominantly local action on the tissue microenvironment and on the epithelial barrier , contributing to the resolution of inflammation without systemic immunosuppressive effects. Recent studies also investigate KPV delivery strategies to improve its stability and experimental bioavailability. [11]


Functional synergies of the blend

Angiogenesis and perfusion. TB-500 and BPC-157 converge on VEGF/vascularization , while GHK-Cu supports endothelial proliferation . KPV contributes indirectly by promoting a controlled inflammatory environment , which supports functional and orderly neoangiogenesis.

Cell migration and ECM. TB-500 optimizes actin polymerization and motility; BPC-157 and GHK-Cu enhance fibroblast activity and collagen/ECM deposition , building a robust scaffold for neovascularization and re-epithelialization. KPV limits cytokine excess that can hinder proliferative phases.

Immunomodulation and redox. The four peptides reduce oxidative stress and pro-inflammatory cytokines through distinct but complementary pathways: BPC-157 realigns the NO/eNOS axis , TB-500 attenuates NF-κB/TLR , GHK-Cu buffers ROS and cooperates in inflammatory resolution, while KPV promotes controlled closure of the local inflammatory phase .


Preclinical applications: muscle-tendon, dermatology and post-surgery

Muscle/tendon. BPC-157 increases GH receptors in local fibroblasts, amplifying anabolic signals at the site without systemic increases; TB-500 accelerates ECM deposition and activates satellite cells for differentiation; GHK-Cu limits oxidative load and excessive scarring , improving the elasticity and quality of newly formed tissue. In combination, faster and more functionally consistent recovery trajectories are observed.

Dermatology and chronic wounds. GHK-Cu is well-established as an active ingredient for dermal repair , texture, and elasticity; coadministration with BPC-157 and TB-500 provides a microenvironment favorable for re-epithelialization, angiogenesis, and controlled remodeling, with potential experimental utility in ulcers and difficult wounds .

Bioburden control. TB-500 exhibits antimicrobial properties and improves antibiotic penetration ; GHK-Cu can generate lipid combinations with antimicrobial activity in situ, reducing bacterial/fungal colonization; BPC-157 increases perfusion and immune recruitment, contributing to a pathogen-hostile environment.


Anti-aging profiles and tissue resilience

Aging is accompanied by a decline in repair , chronic inflammation , and redox dysfunction. TB-500 supports organ regeneration (heart, CNS, cornea, skin, muscle) by activating progenitor cells and protecting mature cells; BPC-157 attenuates ischemic damage and necrosis markers, preserving perfusion and integrity; GHK-Cu modulates broad gene programs, suppresses NF-κB , supports DNA repair and proteasomal function , reducing ROS and cytokines. KPV contributes by maintaining a contained inflammatory response , favoring long-term tissue resilience.


Formats and experimental use

KLOW Blend – Pre-filled Pen 80mg/3ml, Available configurations: BPC-157 10 mg + TB-500 10 mg + GHK-Cu 50 mg + KPV 10 mg (total 80 mg) This set-up simplifies ordering , storage, titration and co-administration , leaving researchers to focus on experimental design, histological/biomechanical outcomes and gene expression analysis .


Research Warnings

Product intended for research use only . Not intended to diagnose, treat, or prevent disease; do not administer to humans or animals outside of authorized settings. An ethical protocol , adequate PPE, and suitable storage conditions are required; include experimental controls, prespecified endpoints , and bias mitigation strategies.

Reviews

There are no reviews yet.

Be the first to review “KLOW Blend – Pre-filled Pen 80mg/3ml”

Your email address will not be published. Required fields are marked *

Scroll to Top